logo-loader
Bodycote Group

Bodycote shares jump as it expects annual revenue and profit ahead of consensus

In a trading update the FTSE 250-listed company said its revenue for the four months ended 30 April 2018 was £243mln, 7% higher than a year ago

bodycote
Bodycote said: “We have seen robust growth in the first four months of the year in spite of the foreign currency headwind”

Bodycote PLC (LON:BOY) shares jumped on Wednesday morning as the company reported solid growth in revenue for the first four months of the current year and said it expects full-year revenue and profit to be higher than previously expected.

In a trading update, the FTSE 250-listed company said its revenue for the four months ended 30 April 2018 was £243mln, 7% higher than a year ago and 10% higher at constant currency.

READ: Bodycote wins 15-year aero engine contract from Rolls-Royce

The heat treatment services provider said on a divisional basis, ADE revenues were up 5% to £94mln, while AGI revenues rose 9% to £149mln, and Specialist Technologies revenue grew 12% at constant currency rates.

The company said overall growth in energy revenues was 24%, with continued strength in onshore North American revenues, as well as early indications of an upturn in Western Europe oil & gas revenues. 

Bodycote said: “We have seen robust growth in the first four months of the year in spite of the foreign currency headwind.”

The company added: “At this early stage, and notwithstanding the Group's limited visibility, the Board now expects full-year revenue to be higher than previously expected and headline operating profit to be slightly ahead of current analysts' consensus.”

In early morning trading, Bodycote’s shares gained 5.9% to 980.50p. 

Quick facts: Bodycote Group

Price: £6.70

Market: LSE
Market Cap: £1.28 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

2 hours, 20 minutes ago

2 min read